Ironwood Pharmaceuticals, Inc. discovers, develops, and commercializes medicines targeting therapeutic needs. The company is developing Linaclotide, a first-in-class compound that is in confirmatory Phase III clinical trials for the treatment of irritable bowel syndrome with constipation, chronic constipation, and other lower gastrointestinal conditions. It also focuses on one Phase I pain drug candidate and multiple preclinical programs, as well as on building a specialty biochemicals business based on a proprietary strain-development platform. The company has a collaboration agreement with Forest Laboratories, Inc. to jointly develop and commercialize linaclotide in North America; a license agreement with Almirall, S.A. to develop and commercialize linaclotide in Europe; a license agreement with Astellas Pharma Inc. that provides Astellas Pharma with the right to develop and commercialize linaclotide in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia. It was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Overview article on Linaclotide, the company's lead drug: http://en.wikipedia.org/wiki/Linaclotide
Updated IRWD short volume numbers (source: www.nasdaq.com)
Settlement Date Short Interest
Total outstanding shares: 120 million (as of 03/31/2014)